The main point of the article is to explain why FDA is not taking action against Spiriva (generic name: tiotropium), a treatment for chronic obstructive pulmonary disorder sold by Boehringer Ingelheim and Pfizer, despite a meta-analysis that raised concerns.
Although, not all drugs surpassed expectations as Nuvigil, their new sleep disorder drug intended to cushion sales once blockbuster sleep drug Provigil faces generic competition, failed to achieve growth targets.